This webinar takes place on Wednesday July 8th between 16.00 and 16.30 CEST / 15.00-15.30 GMT / 10.00-10.30 AM EDT / 7.00-7.30 AM PDT.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Chronic pain represents a major unmet need in drug discovery, affecting hundreds of millions of people globally, while remaining inadequately treated by existing therapies. From a pharmaceutical and translational research standpoint, chronic pain poses unique challenges due to its complex, multifactorial biology and the limited efficacy and safety concerns associated with current analgesics.

In the context of pain, alterations in neuronal excitability are a key mechanism underlying the transition from acute to chronic pain, driven by maladaptive changes within the peripheral and central nervous systems that enhance and sustain pain signaling.

At Cellectricon, we have developed advanced technology platforms and in vitro models to enable high-capacity studies in the field of pain, ranging from basic research to late-stage validation of targets and lead compounds.

In this webinar we will present how Cellectricon’s proprietary optical electrophysiology platform, together with peripheral in vitro pain models, is used for high-capacity studies in the field of chronic pain. The platform, which allows for the detection of alterations to neuronal excitability with high temporal and optical resolution down to the single-cell level, will be reviewed in detail and examples of how this has been used to generate pharmacology data will be presented.

Presented by:

Johan Pihl, CSO

Johan joined Cellectricon in 2005 and has been in R&D as well as commercial positions at the company. He has been involved in the development of Cellectricon’s proprietary technology platforms and intellectual property. Prior to his role as Chief Scientific Officer at Cellectricon, he was developing and overseeing the discovery services as Chief Operating Officer. Johan has a PhD in Chemistry from Chalmers University of Technology, Gothenburg, Sweden, and is the author and co-author of numerous scientific publications and patents.